Perigon Wealth Management LLC Makes New Investment in IQVIA Holdings Inc. $IQV

Perigon Wealth Management LLC acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the second quarter, Holdings Channel.com reports. The fund acquired 2,578 shares of the medical research company’s stock, valued at approximately $498,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in IQV. Financial Freedom LLC acquired a new stake in shares of IQVIA in the 1st quarter worth about $25,000. Ascentis Independent Advisors acquired a new position in IQVIA during the 1st quarter valued at about $25,000. International Assets Investment Management LLC bought a new stake in IQVIA during the 4th quarter worth approximately $27,000. Gilpin Wealth Management LLC bought a new stake in IQVIA during the 4th quarter worth approximately $27,000. Finally, CrossGen Wealth LLC purchased a new stake in shares of IQVIA in the fourth quarter worth approximately $28,000. 89.62% of the stock is owned by institutional investors.

IQVIA Trading Up 4.0%

Shares of IQV stock opened at $249.62 on Thursday. The company has a quick ratio of 0.71, a current ratio of 0.71 and a debt-to-equity ratio of 2.18. The firm has a market cap of $41.09 billion, a P/E ratio of 30.97, a PEG ratio of 2.04 and a beta of 1.18. The company has a 50 day moving average of $210.23 and a 200-day moving average of $186.82. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $251.36.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating the consensus estimate of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The business had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. During the same quarter in the prior year, the business earned $2.81 earnings per share. IQVIA’s revenue for the quarter was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Sell-side analysts anticipate that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA declared that its board has authorized a share repurchase plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s management believes its shares are undervalued.

Insider Transactions at IQVIA

In other IQVIA news, insider W Richard Staub sold 5,500 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the sale, the insider directly owned 13,312 shares of the company’s stock, valued at $3,097,436.16. This represents a 29.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Eric Sherbet sold 5,000 shares of the stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the transaction, the insider owned 20,999 shares of the company’s stock, valued at $5,232,110.84. This represents a 19.23% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 12,913 shares of company stock worth $3,098,793 over the last 90 days. 1.70% of the stock is owned by insiders.

Analysts Set New Price Targets

IQV has been the topic of several analyst reports. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Mizuho raised their price objective on IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. TD Cowen upped their target price on shares of IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. HSBC reiterated a “buy” rating and issued a $240.00 target price on shares of IQVIA in a report on Monday, July 6th. Finally, Weiss Ratings upgraded shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $241.88.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.